ApprovalTrail

Approval · Notice of Compliance 15128 · 2014

BRILINTA: Notice of Compliance 15128

Issued January 15, 2014

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number
15128
Date
January 15, 2014
Company
Astrazeneca Canada IncMississauga, Ontario, Canada
Product type
Prescription Pharmaceutical
Submission
Supplement to a New Drug Submission (SNDS), supplement
Submission class
Other
Reason
To qualify drug substance impurity limits
Therapeutic class
Platelet aggregation inhibitor

Products in this notice

BrandDINStatus today
BRILINTANot yet assigned—

Medicinal ingredients